



Exploration of Antagonist Efficacy for LPrA2 Like Peptide

## Journal of Health Disparities Research and Practice

Volume 9  
Issue 5 *Special Issue - NIDDK STEP UP*

Article 13

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2016

### Exploration of Antagonist Efficacy for LPrA2 Like Peptide

Ayobami Loye

Ruben R. Gonzalez-Perez, PhD , *Morehouse School of Medicine*

Follow this and additional works at: <https://digitalscholarship.unlv.edu/jhdp>



Part of the [Bilingual, Multilingual, and Multicultural Education Commons](#), [Community College Leadership Commons](#), [Higher Education Commons](#), [Immune System Diseases Commons](#), [Public Health Commons](#), [Translational Medical Research Commons](#), and the [Virus Diseases Commons](#)

#### Recommended Citation

Loye, Ayobami and Gonzalez-Perez, PhD, Ruben R. (2016) "Exploration of Antagonist Efficacy for LPrA2 Like Peptide," *Journal of Health Disparities Research and Practice*: Vol. 9: Iss. 5, Article 13.  
Available at: <https://digitalscholarship.unlv.edu/jhdp/vol9/iss5/13>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Journal of Health Disparities Research and Practice by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact [digitalscholarship@unlv.edu](mailto:digitalscholarship@unlv.edu).

---

## Exploration of Antagonist Efficacy for LPrA2 Like Peptide

### Abstract

Leptin is a small protein hormone that controls satiety and is produced by adipocytes. Obese people have increased levels of circulating leptin. Excessive leptin levels cause a break down in the control of leptin signaling pathways leading to increased angiogenesis, proliferation, cell migration, invasion, and anti-apoptotic events. Obesity and leptin signaling have been linked to cancer progression. Literature shows that LPrA2 is an effective leptin antagonist as it decreases proliferation of breast cancer cells in vitro.

This project compares the effectiveness of LPrA2 like compounds in breast cancer cell-line MDA-MB-468 (M-468 BCs). We hypothesize that the new peptide antagonists have shorter sequences than LPrA2 and could be more advantageous inhibitors of leptin signaling in BCs than the original LPrA2. During this study, we first tested toxicity of LPrA2 like peptides in MCF10-A cell-line. Then we tested the effectiveness to inhibit leptin induce S-phase in BCs and compared them to LPrA2. M-468 BCs were treated with various compounds for 48 hours. Cell cycle staging was determined using a cellometer.

Our results show that two of the new peptide antagonists were more effective in S-phase inhibition than LPrA2. We also expect that a combination of the new peptide antagonist and chemotherapy drug will inhibit proliferation in vitro.

This study could lead to the development of future studies that test the efficacy of C6 and C8 using an in vivo mouse model.

### Keywords

Leptin; Obesity; Breast Cancer; Leptin Antagonist (LPrA2)



**Journal of Health Disparities Research and Practice**  
**Volume 9, Special Edition 1, Summer 2016, pp. 22**

© 2011 Center for Health Disparities Research

School of Community Health Sciences

University of Nevada, Las Vegas

## **Exploration of Antagonist Efficacy for LPrA2 Like Peptide**

Ayobami Loye

Ruben R. Gonzalez-Perez, PhD, Morehouse School of Medicine

**Coordinating Center:** Charles R. Drew University of Medicine and Science

### **ABSTRACT**

Leptin is a small protein hormone that controls satiety and is produced by adipocytes. Obese people have increased levels of circulating leptin. Excessive leptin levels cause a break down in the control of leptin signaling pathways leading to increased angiogenesis, proliferation, cell migration, invasion, and anti-apoptotic events. Obesity and leptin signaling have been linked to cancer progression. Literature shows that LPrA2 is an effective leptin antagonist as it decreases proliferation of breast cancer cells in vitro.

This project compares the effectiveness of LPrA2 like compounds in breast cancer cell-line MDA-MB-468 (M-468 BCs). We hypothesize that the new peptide antagonists have shorter sequences than LPrA2 and could be more advantageous inhibitors of leptin signaling in BCs than the original LPrA2. During this study, we first tested toxicity of LPrA2 like peptides in MCF10-A cell-line. Then we tested the effectiveness to inhibit leptin induce S-phase in BCs and compared them to LPrA2. M-468 BCs were treated with various compounds for 48 hours. Cell cycle staging was determined using a cellometer.

Our results show that two of the new peptide antagonists were more effective in S-phase inhibition than LPrA2. We also expect that a combination of the new peptide antagonist and chemotherapy drug will inhibit proliferation in vitro.

This study could lead to the development of future studies that test the efficacy of C6 and C8 using an in vivo mouse model.

**Key words:** Leptin, Obesity, Breast Cancer, Leptin Antagonist (LPrA2)

### **ACKNOWLEDGEMENTS**

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, Grant Number: 5R25DK078384-09.